Investor Relations Media Center Careers Contact Home Our Company Our Experience Our Divisions Home » Sitemap Home Our Company Our Story Future Directions Leadership Facilities Our Experience Technology Innovation Products and Pipeline Partners Our Divisions Global Pharma (Generics) Impax Pharma (Branded) Investor Relations Media Center Press Releases Download Library Careers Working at Impax Benefits Opportunities US Openings Taiwan Affirmative Action Directions Contact Privacy Policy Legal Notices Sitemap Contact Copyright © 2014 Impax Laboratories, Inc. All rights reserved. Privacy Policy Legal Notices Purchase Order Terms and Conditions Sitemap

Investor Relations Media Center Careers Contact Home Our Company Our Experience Our Divisions Our Experience Technology Innovation Products and Pipeline Partners Home » Our Experience » Products and Pipeline Impax’s ongoing strategy to invest in R&D to develop high-value opportunities should continue to provide the potential for growth in the future. We currently manufacture and market 133 generic pharmaceutical products, which represent dosage variations of 39 different pharmaceutical compounds through our Global Pharmaceuticals division; another 14 of our generic pharmaceutical products representing dosage variations of four different pharmaceutical compounds are marketed by our alliance agreement partners. A list of our currently marketed generic products can be found here. Impax Pharmaceuticals, our branded division, is currently promoting Zomig® nasal spray in the United States. We currently have 44 pending Abbreviated New Drug Applications (ANDA) at the FDA. We are also working on an additional 25 products under development with many having the potential to be first-to-file or first-to-market opportunities. Learn more about our generic pharmaceuticals division. One late-stage branded pharmaceutical product candidate which we are developing internally, RYTARY™ (IPX066), an extended release capsule formulation of carbidopa-levodopa for the treatment of symptomatic Parkinson’s disease, for which an NDA was accepted for filing by the FDA in February 2012. In January 2013, the FDA issued a Complete Response Letter regarding the NDA for RYTARY™. We are working with the FDA on the appropriate next steps for the RYTARY™ NDA. The Company currently has four additional neurology products in various stages of development and review by its R&D team. Learn more about our brand pharmaceuticals division. Top Technology Innovation Global Pharmaceuticals Impax Pharmaceuticals Phone: (510) 240-6000 Fax: (510) 471-3200 Philadelphia Phone: (215) 613-2400 Fax: (215) 613-2406 New Britain Phone: (215) 558-4300 Fax: (215) 558-4333 Phone: +886-37-586-268 Copyright © 2014 Impax Laboratories, Inc. All rights reserved. Privacy Policy Legal Notices Purchase Order Terms and Conditions Sitemap